The jury, which started deliberating Thursday afternoon, also found that sequencers sold by BGI’s Complete Genomics Inc. infringe two of three Illumina patents, but it said all three shouldn’t have been issued in the first place, mooting any potential award, according to the verdict issued in the U.S. District Court for the District of Delaware.
The ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.